Senzime strengthens the management team within Sales and Marketing
Press release: Uppsala, March 28, 2019. Senzime AB (publ) today announced that the management team is strengthened with a VP Sales and a VP Marketing and Business development. This is in line with Senzime’s clear focus on international commercialization.
Anders Selin assumes the position as VP Sales at Senzime. Anders has over 20 years of experience in leading roles in sales at global medical technology companies based in Europe, the Middle East and Asia. Anders is currently head of strategic programs and projects at Karolinska Sjukhuset as well as acting head of development and management of medical care technology. Anders will take office on September 1, 2019.
Catrin Molund is promoted VP Marketing and Business development at Senzime. Catrin is currently responsible for marketing and business development and she has over 19 years of experience in life-science from companies such as Orexo, Phadia, Amersham Biosciences and Pyrosequencing.
“After developing our efficient, certified and approved solutions, we have started the rollout of TetraGraph. It is a new and important chapter in the company's history and a step towards our ambition to become a world leader in patient monitoring. We know that surgeons, anesthetists and healthcare professionals need to be able to better monitor patients before, during and after surgery. We are in a commercialization phase where Anders Selin and his many years of experience will be of great value for us. As part of our clear focus on sales and market presence, I am also very pleased to promote Catrin Molund as VP Marketing and Business development,” says Pia Renaudin, CEO of Senzime.
Anders Selin and Catrin Molund will both be members of the Senzime management team.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, email@example.com, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on March 28th, 2019, 10:00